Bahl & Gaynor’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $743K | Sell |
1,512
-380
| -20% | -$206K | ﹤0.01% | 254 |
|
|
2025
Q4 | $1.1M | Hold |
1,892
| – | – | 0.01% | 234 |
|
|
2025
Q3 | $918K | Buy |
1,892
+47
| +3% | +$21.9K | ﹤0.01% | 238 |
|
|
2025
Q2 | $748K | Sell |
1,845
-4
| -0.2% | -$1.67K | ﹤0.01% | 258 |
|
|
2025
Q1 | $920K | Sell |
1,849
-12
| -0.6% | -$6.5K | ﹤0.01% | 248 |
|
|
2024
Q4 | $968K | Sell |
1,861
-25
| -1% | -$13.7K | 0.01% | 245 |
|
|
2024
Q3 | $1.17M | Sell |
1,886
-1,320
| -41% | -$781K | 0.01% | 242 |
|
|
2024
Q2 | $1.77M | Sell |
3,206
-125
| -4% | -$71.6K | 0.01% | 215 |
|
|
2024
Q1 | $1.94M | Buy |
3,331
+40
| +1% | +$22.4K | 0.01% | 212 |
|
|
2023
Q4 | $1.75M | Sell |
3,291
-75
| -2% | -$36.3K | 0.01% | 214 |
|
|
2023
Q3 | $1.7M | Buy |
3,366
+156
| +5% | +$83.1K | 0.01% | 212 |
|
|
2023
Q2 | $1.67M | Sell |
3,210
-1,624
| -34% | -$876K | 0.01% | 219 |
|
|
2023
Q1 | $2.79M | Buy |
4,834
+6
| +0.1% | +$3.38K | 0.02% | 193 |
|
|
2022
Q4 | $2.66M | Sell |
4,828
-1,010
| -17% | -$535K | 0.02% | 188 |
|
|
2022
Q3 | $2.96M | Sell |
5,838
-144
| -2% | -$80.6K | 0.02% | 181 |
|
|
2022
Q2 | $3.25M | Sell |
5,982
-470
| -7% | -$259K | 0.02% | 186 |
|
|
2022
Q1 | $3.81M | Sell |
6,452
-1
| -0% | -$574 | 0.03% | 178 |
|
|
2021
Q4 | $4.31M | Buy |
6,453
+195
| +3% | +$122K | 0.02% | 179 |
|
|
2021
Q3 | $3.58M | Buy |
6,258
+1,000
| +19% | +$549K | 0.02% | 184 |
|
|
2021
Q2 | $2.65M | Sell |
5,258
-2,502
| -32% | -$1.18M | 0.02% | 216 |
|
|
2021
Q1 | $3.54M | Sell |
7,760
-1,387
| -15% | -$662K | 0.02% | 190 |
|
|
2020
Q4 | $4.26M | Buy |
9,147
+428
| +5% | +$201K | 0.03% | 172 |
|
|
2020
Q3 | $3.85M | Sell |
8,719
-849
| -9% | -$351K | 0.03% | 166 |
|
|
2020
Q2 | $3.47M | Sell |
9,568
-141
| -1% | -$47.3K | 0.03% | 167 |
|
|
2020
Q1 | $2.75M | Buy |
9,709
+1,444
| +17% | +$455K | 0.02% | 181 |
|
|
2019
Q4 | $2.69M | Sell |
8,265
-334
| -4% | -$101K | 0.02% | 212 |
|
|
2019
Q3 | $2.5M | Buy |
8,599
+63
| +0.7% | +$18K | 0.02% | 212 |
|
|
2019
Q2 | $2.51M | Buy |
8,536
+5,034
| +144% | +$1.39M | 0.02% | 206 |
|
|
2019
Q1 | $959K | Buy |
3,502
+387
| +12% | +$96.3K | 0.01% | 271 |
|
|
2018
Q4 | $697K | Sell |
3,115
-160
| -5% | -$37.5K | 0.01% | 276 |
|
|
2018
Q3 | $799K | Sell |
3,275
-400
| -11% | -$92K | 0.01% | 277 |
|
|
2018
Q2 | $761K | Sell |
3,675
-505
| -12% | -$107K | 0.01% | 286 |
|
|
2018
Q1 | $863K | Sell |
4,180
-144
| -3% | -$30.2K | 0.01% | 290 |
|
|
2017
Q4 | $821K | Sell |
4,324
-36
| -0.8% | -$6.9K | 0.01% | 293 |
|
|
2017
Q3 | $825K | Sell |
4,360
-50
| -1% | -$9.05K | 0.01% | 279 |
|
|
2017
Q2 | $769K | Sell |
4,410
-72
| -2% | -$12.1K | 0.01% | 291 |
|
|
2017
Q1 | $688K | Buy |
4,482
+42
| +0.9% | +$6.42K | 0.01% | 294 |
|
|
2016
Q4 | $627K | Sell |
4,440
-6
| -0.1% | -$885 | 0.01% | 300 |
|
|
2016
Q3 | $707K | Sell |
4,446
-164
| -4% | -$25.3K | 0.01% | 281 |
|
|
2016
Q2 | $681K | Sell |
4,610
-72
| -2% | -$10.6K | 0.01% | 272 |
|
|
2016
Q1 | $663K | Buy |
4,682
+1,087
| +30% | +$146K | 0.01% | 274 |
|
|
2015
Q4 | $510K | Sell |
3,595
-200
| -5% | -$26.7K | 0.01% | 311 |
|
|
2015
Q3 | $464K | Buy |
3,795
+65
| +2% | +$8.47K | 0.01% | 322 |
|
|
2015
Q2 | $484K | Buy |
3,730
+524
| +16% | +$68.3K | 0.01% | 324 |
|
|
2015
Q1 | $431K | Buy |
3,206
+966
| +43% | +$125K | 0.01% | 324 |
|
|
2014
Q4 | $281K | Buy |
+2,240
| New | +$272K | ﹤0.01% | 374 |
|
Other funds holding TMO
VCM
Bahl & Gaynor's TMO Position: Q1 2026 in Review
Bahl & Gaynor reduced its Thermo Fisher Scientific (TMO) stake by 20% in Q1 2026, selling an estimated $206K and leaving 1,512 shares worth $743K. The position accounts for ﹤0.01% of the portfolio, ranked #254.
Bahl & Gaynor first reported a position in TMO in Q4 2014 and has held it in 46 quarters since. The position peaked at $4.31M in Q4 2021. 2,594 funds tracked by Wall St. Rank hold TMO as of Q1 2026.
- Bahl & Gaynor held 1,512 shares of Thermo Fisher Scientific worth $743K as of Q1 2026.
- Bahl & Gaynor sold 380 Thermo Fisher Scientific shares in Q1 2026, an estimated $206K.
- Thermo Fisher Scientific made up ﹤0.01% of Bahl & Gaynor's portfolio in Q1 2026, its #254 holding.
- Bahl & Gaynor first reported a position in Thermo Fisher Scientific in Q4 2014 and has held it in 46 quarters since.
- Bahl & Gaynor's Thermo Fisher Scientific position peaked at $4.31M in Q4 2021.
- 2,594 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.
Based on Bahl & Gaynor's 13F filing for Q1 2026, filed 7 May 2026.